These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25672578)

  • 1. Using the Lymph Node Ratio to Evaluate the Prognosis of Stage II/III Breast Cancer Patients Who Received Neoadjuvant Chemotherapy and Mastectomy.
    Wu SG; Li Q; Zhou J; Sun JY; Li FY; Lin Q; Lin HX; Gaun XX; He ZY
    Cancer Res Treat; 2015 Oct; 47(4):757-64. PubMed ID: 25672578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy.
    Xin F; Yu Y; Yang ZJ; Hou LK; Mao JF; Xia L; Wang X; Cao XC
    Tumour Biol; 2016 Jun; 37(6):8445-54. PubMed ID: 26733172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy.
    Koo T; Song C; Kim JS; Kim K; Chie EK; Kang SB; Lee KW; Kim JH; Jeong SY; Kim TY
    PLoS One; 2015; 10(9):e0138728. PubMed ID: 26381522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. Results from a multicentre study.
    Saxena N; Hartman M; Aziz R; Rapiti E; Bhoo Pathy N; Lim SE; Iau P; Taib NA; Schaffar R; Neyroud-Caspar I; Yip CH; Lee SC; Verkooijen HM
    Eur J Cancer; 2011 May; 47(8):1186-92. PubMed ID: 21239165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymph node counts and ratio in axillary dissections following neoadjuvant chemotherapy for breast cancer: a better alternative to traditional pN staging.
    Chen S; Liu Y; Huang L; Chen CM; Wu J; Shao ZM
    Ann Surg Oncol; 2014 Jan; 21(1):42-50. PubMed ID: 24013900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study.
    Kim SH; Jung KH; Kim TY; Im SA; Choi IS; Chae YS; Baek SK; Kang SY; Park S; Park IH; Lee KS; Choi YJ; Lee S; Sohn JH; Park YH; Im YH; Ahn JH; Kim SB; Kim JH
    Cancer Res Treat; 2016 Oct; 48(4):1373-1381. PubMed ID: 27034147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05).
    Shim SJ; Park W; Huh SJ; Choi DH; Shin KH; Lee NK; Suh CO; Keum KC; Kim YB; Ahn SD; Kim SS; Ha SW; Chie EK; Kim K; Shin HS; Kim JH; Lee HS
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):65-72. PubMed ID: 24161425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Lymph Node Ratio in Breast Cancer Patients with Adequate Pathologic Evidence After Neoadjuvant Chemotherapy.
    Ai X; Liao X; Wang M; Hu Y; Li J; Zhang Y; Tang P; Jiang J
    Med Sci Monit; 2020 Apr; 26():e922420. PubMed ID: 32348295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.
    Tsai J; Bertoni D; Hernandez-Boussard T; Telli ML; Wapnir IL
    Ann Surg Oncol; 2016 Oct; 23(10):3310-6. PubMed ID: 27401442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using the lymph nodal ratio to predict the risk of locoregional recurrence in lymph node-positive breast cancer patients treated with mastectomy without radiation therapy.
    Wu SG; Chen Y; Sun JY; Li FY; Lin Q; Lin HX; He ZY
    Radiat Oncol; 2013 May; 8():119. PubMed ID: 23672513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy.
    Agarwal R; Philip A; Pavithran K; Rajanbabu A; Goel G; Vijaykumar DK
    Indian J Cancer; 2019; 56(3):228-235. PubMed ID: 31389386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Number of negative lymph nodes can predict survival of breast cancer patients with four or more positive lymph nodes after postmastectomy radiotherapy.
    Wu SG; Sun JY; Zhou J; Li FY; Zhou H; Lin Q; Lin HX; Bao Y; He ZY
    Radiat Oncol; 2014 Dec; 9():284. PubMed ID: 25511525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
    Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
    Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
    White R; Dinneen T; Makris A
    Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy].
    Rong QL; Wang SL; Tang Y; Jin J; Song YW; Wang WH; Liu YP; Fang H; Ren H; Liu XF; Yu ZH; Li YX
    Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):445-452. PubMed ID: 28635235
    [No Abstract]   [Full Text] [Related]  

  • 17. Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy.
    Le Scodan R; Selz J; Stevens D; Bollet MA; de la Lande B; Daveau C; Lerebours F; Labib A; Bruant S
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e1-7. PubMed ID: 21377284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stage-to-stage comparison of neoadjuvant chemotherapy versus adjuvant chemotherapy in pathological lymph node positive breast cancer patients.
    Lee NK; Shin KH; Park IH; Lee KS; Ro J; Jung SY; Lee S; Kim SW; Kim TH; Kim JY; Kang HS; Cho KH
    Jpn J Clin Oncol; 2012 Nov; 42(11):995-1001. PubMed ID: 22911001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmastectomy Radiation Therapy Based on Pathologic Nodal Status in Clinical Node-Positive Stage II to III Breast Cancer Treated with Neoadjuvant Chemotherapy.
    Huang Z; Zhu L; Huang XB; Tang Y; Rong QL; Shi M; Wang WH; Tie J; Shen LF; Chen JY; Zhang J; Wu HF; Cheng J; Liu M; Tan YT; Ma CY; Wang SL; Li YX
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):1030-1039. PubMed ID: 32585337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy.
    Fischer LK; Katz MH; Lee SM; Liu L; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Roland CL; Fleming JB; Estrella J; Rashid A; Wang H
    Histopathology; 2016 Jan; 68(2):210-20. PubMed ID: 25945396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.